

Trying 31060000009999...Open

DIALOG INFORMATION SERVICES  
PLEASE LOGON:  
\*\*\*\*\* HHHHHHHH SSSSSSS? ### Status: Signing onto Dialog \*\*\*\*\*  
ENTER PASSWORD:  
\*\*\*\*\* HHHHHHHH SSSSSSS? \*\*\*\*\*  
Welcome to DIALOG

### Status: Login successfulDialog level 05.20.01D

Last logoff: 21dec07 14:10:24  
Logon file405 23jan08 10:56:52  
\*\*\* ANNOUNCEMENTS \*\*\*  
\*\*\*  
\*\*\*The 2008 EMTREE Thesaurus has been added to EMBASE (Files 72, 73, 772, and 972)

NEW FILES RELEASED  
\*\*\*Trademarkscan - South Korea (File 655)

RESUMED UPDATING  
\*\*\*File 154 & F155, MEDLINE  
\*\*\*File 156, ToxFile  
\*\*\*  
RELOADS COMPLETED  
\*\*\*Files 72 & 73, EMBASE  
\*\*\*Files 340, 341 & 942, CLAIMS/U.S. Patents - 2006 reload now online  
\*\*\*  
NEWS  
Chemical Structure Searching now available in Prous Science Drug Data Report (F452), Prous Science Drugs of the Future (F453), IMS R&D Focus (F445/955), Pharmaprojects (F128/928), Beilstein Facts (F390), Derwent Chemistry Resource (F355) and Index Chemicus (File 302).  
\*\*\*  
>>>For the latest news about Dialog products, services, content<<<  
>>>and events, please visit What's New from Dialog at <<<  
>>><http://www.dialog.com/whatsnew/>. You can find news about<<<  
>>>a specific database by entering HELP NEWS <file number>.<<<  
\* \* \*  
SYSTEM:HOME  
Cost is in DialUnits  
Menu System II: D2 version 1.8.0 term=ASCII  
\*\*\* DIALOG HOMEBASE(SM) Main Menu \*\*\*

Information:  
1. Announcements (new files, reloads, etc.)  
2. Database, Rates, & Command Descriptions  
3. Help in Choosing Databases for Your Topic  
4. Customer Services (telephone assistance, training, seminars, etc.)  
5. Product Descriptions

Connections:  
6. DIALOG(R) Document Delivery  
7. Data Star(R)

(c) 2003 Dialog, a Thomson business. All rights reserved.

/H = Help

/L = Logoff

/NOMENU = Command Mode

Enter an option number to view information or to connect to an online service. Enter a BEGIN command plus a file number to search a database (e.g., B1 for ERIC).

?

Terminal set to DLINK

\*\*\* DIALOG HOMEBASE(SM) Main Menu \*\*\*

Information:

1. Announcements (new files, reloads, etc.)
2. Database, Rates, & Command Descriptions
3. Help in Choosing Databases for Your Topic
4. Customer Services (telephone assistance, training, seminars, etc.)
5. Product Descriptions

Connections:

6. DIALOG(R) Document Delivery
7. Data Star(R)

(c) 2003 Dialog, a Thomson business. All rights reserved.

/H = Help

/L = Logoff

/NOMENU = Command Mode

Enter an option number to view information or to connect to an online service. Enter a BEGIN command plus a file number to search a database (e.g., B1 for ERIC).

? b biosci

```
>>>      44 is unauthorized
>>>      76 is unauthorized
>>>2 of the specified files are not available
      23jan08 10:57:01 User276653 Session D136.1
      $0.00    0.267 DialUnits FileHomeBase
      $0.00  Estimated cost FileHomeBase
      $0.03  TELNET
      $0.03  Estimated cost this search
      $0.03  Estimated total session cost  0.267 DialUnits
```

SYSTEM:OS - DIALOG OneSearch

File	5:Biosis Previews(R) 1926-2008/Jan W3
	(c) 2008 The Thomson Corporation
File	24:CSA Life Sciences Abstracts 1966-2007/Aug
	(c) 2007 CSA.
File	28:Oceanic Abstracts 1966-2007/Oct
	(c) 2007 CSA.
File	34:SciSearch(R) Cited Ref Sci 1990-2008/Jan W2
	(c) 2008 The Thomson Corp
File	35:Dissertation Abs Online 1861-2007/Oct
	(c) 2007 ProQuest Info&Learning
File	40:Enviroline(R) 1975-2008/Jan
	(c) 2008 Congressional Information Service

File 41:Pollution Abstracts 1966-2007/Sep  
(c) 2007 CSA.  
File 45:EMCare 2008/Jan W2  
(c) 2008 Elsevier B.V.  
File 50:CAB Abstracts 1972-2008/Dec  
(c) 2008 CAB International  
File 65:Inside Conferences 1993-2008/Jan 21  
(c) 2008 BLDSC all rts. reserv.  
File 71:ELSEVIER BIOBASE 1994-2008/Jan W3  
(c) 2008 Elsevier B.V.  
File 73:EMBASE 1974-2008/Jan 23  
(c) 2008 Elsevier B.V.  
**\*File 73: The 2008 EMTREE Thesaurus has been loaded. Please see HELP NEWS 72 for details.**  
File 91:MANTIS(TM) 1880-2007/Apr  
2001 (c) Action Potential  
**\*File 91: This database has stopped updating temporarily. Please see HELP NEWS 91 for details.**  
File 98:General Sci Abs 1984-2007/Dec  
(c) 2007 The HW Wilson Co.  
File 110:WasteInfo 1974-2002/Jul  
(c) 2002 AEA Techn Env.  
**\*File 110: This file is closed (no updates)**  
File 135:NewsRx Weekly Reports 1995-2008/Jan W2  
(c) 2008 NewsRx  
File 136:BioEngineering Abstracts 1966-2007/Jan  
(c) 2007 CSA.  
File 143:Biol. & Agric. Index 1983-2008/Dec  
(c) 2008 The HW Wilson Co  
File 144:Pascal 1973-2008/Jan W2  
(c) 2008 INIST/CNRS  
File 155:MEDLINE(R) 1950-2008/Jan 21  
(c) format only 2008 Dialog  
**\*File 155: MEDLINE has resumed updating. Please see HELP NEWS 154 for details.**  
File 164:Allied & Complementary Medicine 1984-2008/Jan  
(c) 2008 BLHCIS  
File 172:EMBASE Alert 2008/Jan 01  
(c) 2008 Elsevier B.V.  
File 185:Zoological Record Online(R) 1864-2008/Feb  
(c) 2008 The Thomson Corp.  
**\*File 185: The file has been reloaded to add archive records back to 1864. Accession numbers have changed.**  
File 357:Derwent Biotech Res. \_1982-2008/Dec W4  
(c) 2008 The Thomson Corp.  
File 369:New Scientist 1994-2007/Sep W4  
(c) 2007 Reed Business Information Ltd.  
File 370:Science 1996-1999/Jul W3  
(c) 1999 AAAS  
**\*File 370: This file is closed (no updates). Use File 47 for more current information.**  
File 391:Beilstein Database - Reactions 2007/Q3  
(c) 2007 Beilstein GmbH  
File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec  
(c) 2006 The Thomson Corp  
File 467:ExtraMED(tm) 2000/Dec  
(c) 2001 Informania Ltd.

Set	Items	Description
? s	fibronectin	
	S1	160304 FIBRONECTIN
? s	s1 and precipitat?	
	S1	160304 S1
	S2	725879 PRECIPITAT?
	S2	1379 S1 AND PRECIPITAT?
? s	s2 and factor	
	S2	1379 S2
	S3	6388201 FACTOR
	S3	327 S2 AND FACTOR
? s	s2 and bovine(n)blood(n)serum	
Processing		
Processed	20 of 29 files ...	
Completed processing all files		
	S2	1379 S2
	S2	987825 BOVINE
	S2	9978439 BLOOD
	S2	3250973 SERUM
	S2	342 BOVINE(N)BLOOD(N)SERUM
S4	2	S2 AND BOVINE(N)BLOOD(N)SERUM
? t	s4/9,k/1-2	

4/9,K/1 (Item 1 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

07313370 BIOSIS NO.: 198478048777  
**A SIMPLE AND EFFECTIVE ADDITIONAL STEP IN PURIFICATION OF BOVINE BLOOD SERUM FIBRONECTIN**  
AUTHOR: ZYKOVA T A (Reprint); ZLATOPOL'SKII A D; MAZUROV V I  
AUTHOR ADDRESS: INST BIOL MED CHEM, ACAD MED SCI USSR, MOSCOW, USSR\*\*USSR  
JOURNAL: Voprosy Meditsinskoi Khimii 25 (5): p114-117 1983  
ISSN: 0042-8809  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: RUSSIAN

**ABSTRACT:** Preparations of **fibronectin** from **bovine blood serum**, obtained by means of affinity chromatography on collagen-Sepharose, contained Ig and other proteins, concentration of which constituted 48 .+- 5%. Differential salting out of **fibronectin** and other non-**fibronectin** proteins, using 0.8-2.0 M ammonium sulfate at pH 5.0, demonstrated that **precipitation** of **fibronectin** occurred more effectively as compared with non-**fibronectin** proteins at all the salt concentrations studied. If 0.8 M or 1.0 M ammonium sulfate concentrations were used, the **fibronectin** preparations contained < 10% of other proteins and **fibronectin** loss was about 20%. Salting out of **fibronectin** is an effective additional step of its purification.

REGISTRY NUMBERS: 7783-20-2: AMMONIUM SULFATE  
DESCRIPTORS: AMMONIUM SULFATE IMMUNO GLOBULIN/  
DESCRIPTORS:

MAJOR CONCEPTS: Biochemistry and Molecular Biophysics; Blood and Lymphatics--Transport and Circulation

BIOSYSTEMATIC NAMES: Bovidae--Artiodactyla, Mammalia, Vertebrata, Chordata, Animalia  
COMMON TAXONOMIC TERMS: Animals; Artiodactyls; Chordates; Mammals; Nonhuman Vertebrates; Nonhuman Mammals; Vertebrates  
CHEMICALS & BIOCHEMICALS: AMMONIUM SULFATE

CONCEPT CODES:

10054 Biochemistry methods - Proteins, peptides and amino acids  
10058 Biochemistry methods - Carbohydrates  
10064 Biochemistry studies - Proteins, peptides and amino acids  
10068 Biochemistry studies - Carbohydrates  
10506 Biophysics - Molecular properties and macromolecules  
15001 Blood - General and methods  
15002 Blood - Blood and lymph studies  
34502 Immunology - General and methods

BIOSYSTEMATIC CODES:  
85715 Bovidae

**A SIMPLE AND EFFECTIVE ADDITIONAL STEP IN PURIFICATION OF BOVINE BLOOD SERUM FIBRONECTIN**

ABSTRACT: Preparations of **fibronectin** from **bovine blood serum**, obtained by means of affinity chromatography on collagen-Sepharose, contained Ig and other proteins, concentration of which constituted 48 +/- 5%. Differential salting out of **fibronectin** and other non-**fibronectin** proteins, using 0.8-2.0 M ammonium sulfate at pH 5.0, demonstrated that **precipitation** of **fibronectin** occurred more effectively as compared with non-**fibronectin** proteins at all the salt concentrations studied. If 0.8 M or 1.0 M ammonium sulfate concentrations were used, the **fibronectin** preparations contained < 10% of other proteins and **fibronectin** loss was about 20%. Salting out of **fibronectin** is an effective additional step of its purification.

4/9,K/2 (Item 1 from file: 155)

DIALOG(R)File 155: MEDLINE(R)

(c) format only 2008 Dialog. All rts. reserv.

06266345 PMID: 6649521

[A simple and effective step in the purification of bovine blood fibronectin ]

Prostocin i effektivnyi dopolnitel'nyi etap ochistki fibronektina syvorotki byka.

Zykov A; Zlatopol'skii A D; Mazurov V I

Voprosy medit sinskoi khimii (USSR) Sep-Oct 1983, 29 (5) p114-7,

ISSN 0042-8809--Print Journal Code: 0416601

Publishing Model Print

Document type: English Abstract; Journal Article

Languages: RUSSIAN

Main Citation Owner: NLM

Record type: MEDLINE; Completed

Subfile: INDEX MEDICUS

Preparations of **fibronectin** from **bovine blood serum**, obtained by means of affinity chromatography on collagen-Sepharose, contained immunoglobulins and other proteins, concentration of which constituted 48 +/- 5%. Differential salting out of **fibronectin** and other non-**fibronectin** proteins, using 0.8-2.0 M ammonium sulfate at pH 5.0, demonstrated that **precipitation** of **fibronectin** occurred more

effectively as compared with non- **fibronectin** proteins at all the salt concentrations studied. If 0.8 M or 1.0 M ammonium sulfate concentrations were used, the **fibronectin** preparations contained less than 10% of other proteins and **fibronectin** loss was about 20%. Salting out of **fibronectin** is an effective additional step of its purification.

Descriptors: \*Fibronectins--blood--BL; Animals; Cattle; Chromatography, Affinity--methods--MT; Collagen; Fibronectins--isolation and purification --IP; Osmolar Concentration; Sepharose--analogs and derivatives--AA

CAS Registry No.: 0 (Fibronectins); 9007-34-5 (Collagen); 9012-36-6 (Sephadex)

Record Date Created: 19840107

Record Date Completed: 19840107

[A simple and effective step in the purification of bovine blood fibronectin ]

Preparations of **fibronectin** from bovine blood serum, obtained by means of affinity chromatography on collagen-Sephadex, contained immunoglobulins and other proteins, concentration of which constituted 48 +/- 5%. Differential salting out of **fibronectin** and other non-**fibronectin** proteins, using 0.8-2.0 M ammonium sulfate at pH 5.0, demonstrated that precipitation of **fibronectin** occurred more effectively as compared with non-**fibronectin** proteins at all the salt concentrations studied. If 0.8 M or 1.0 M ammonium sulfate concentrations were used, the **fibronectin** preparations contained less than 10% of other proteins and **fibronectin** loss was about 20%. Salting out of **fibronectin** is an effective additional step of its purification.

? s s3 and purif?

327 S3

2431983 PURIF?

S5 105 S3 AND PURIF?

? s s5 and von(n)willebrand

105 S5

885803 VON

70180 WILLEBRAND

68687 VON(N)WILLEBRAND

S6 22 S5 AND VON(N)WILLEBRAND

? s s5 and coagulation

105 S5

380553 COAGULATION

S7 12 S5 AND COAGULATION

? t s7/6,k/1-12

7/6,K/1 (Item 1 from file: 5)

DIALOG(R)File 5:(c) 2008 The Thomson Corporation. All rts. reserv.

14475793 BIOSIS NO.: 199800270040

Enzymatic and kinetic properties of blood coagulation factor XIIIa and guinea pig liver transglutaminase utilizing

(6-(N-(4-aminobutyl)-N-ethylamino)-2,3-dihydrophthalazine-1,4-dione, as a novel, specific and sensitive chemiluminescent substrate

1998

Enzymatic and kinetic properties of blood coagulation factor XIIIa and guinea pig liver transglutaminase utilizing

(6-(N-(4-aminobutyl)-N-ethylamino)-2,3...

...ABSTRACT: novel and sensitive chemiluminescent assay is described to

quantitate the acyl transfer activities of blood **coagulation factor XIIIa** or liver transglutaminase using aminobutyl-N-ethylisoluminol as acyl acceptor and N,N-dimethylcasein, human plasma fibrinogen or **fibronectin** as acyl donors. The method involved covalently linking aminobutyl-N-ethyl-isoluminol through its free...

...protein-bound glutamine resulting in an isopeptide bond; a reaction catalysed by both transglutaminase and **factor XIIIa**. The protein-bound aminobutyl-N-ethyl-isoluminol was separated from non-conjugated amine by **precipitation** with trichloroacetic acid. The protein-amine conjugate was dissolved in 500 mmol/L NaOH, oxidized...

...ammonium persulphate and light emission quantitated using a luminometer. Optimal conditions were established to detect **factor XIIIa** and transglutaminase activities with the chemiluminescent assay. Specificity was demonstrated by lack of activity in the presence of ethylenediamine tetra-acetic acid or unactivated **factor XIII**, or boiled enzymes, and by competitive inhibition with putrescine and 5'-(biotinamido) pentylamine. The enzymatic and kinetic properties of **factor XIIIa** and transglutaminase in utilizing aminobutyl-N-ethyl-isoluminol as an acyl acceptor substrate were comprehensively documented. The reaction could be carried out in either a **purified** system or a complex plasma or cell lysates milieu. The assay is sensitive, specific, and...

DESCRIPTORS:

CHEMICALS & BIOCHEMICALS: ... **factor XIIIa**

MISCELLANEOUS TERMS: blood **coagulation**

7/6,K/2 (Item 2 from file: 5)

DIALOG(R)File 5:(c) 2008 The Thomson Corporation. All rts. reserv.

09326998 BIOSIS NO.: 198936035889  
PURIFICATION OF BLOOD COAGULATION FACTOR **VIII** BY PRECIPITATION WITH  
SULFATE POLYSACCHARIDES US PATENT-4789733. DECEMBER 6 1988  
1988

PURIFICATION OF BLOOD COAGULATION FACTOR **VIII** BY PRECIPITATION WITH  
SULFATE POLYSACCHARIDES US PATENT-4789733. DECEMBER 6 1988

...REGISTRY NUMBERS: **FACTOR VIII**...

... **FACTOR VIII**...

... **FACTOR VIII**

DESCRIPTORS: USCL-530-383 FIBRINOGEN **FIBRONECTIN** SUPERNATANT TEMPERATURE  
DESCRIPTORS:

CHEMICALS & BIOCHEMICALS: **FACTOR VIII**...

... **FACTOR VIII**...

... **FACTOR VIII**

7/6,K/3 (Item 3 from file: 5)

DIALOG(R)File 5:(c) 2008 The Thomson Corporation. All rts. reserv.

07700943 BIOSIS NO.: 198580009838

COAGULATION PROTEINS SHOWING ABNORMAL ELECTROPHORETIC MOBILITY IN

COMMERCIAL CONCENTRATES OF FACTOR -VIII AND PROTHROMBIN COMPLEX  
1984

COAGULATION PROTEINS SHOWING ABNORMAL ELECTROPHORETIC MOBILITY IN  
COMMERCIAL CONCENTRATES OF FACTOR -VIII AND PROTHROMBIN COMPLEX

ABSTRACT: Five commercial factor VIII (FVIII) concentrates and 3 prothrombin complex concentrates (PCC) were studied with reference to the qualitative evaluation of factors II, IX, **fibronectin**, .alpha.2-antiplasmin (.alpha.2-AP), antithrombin III (AT-III) and subunits A and S of FXIII by crossed-immunolectrophoresis (CIE) and von Willebrand **factor** antigen (vWF:Ag) by radio-CIE. This latter protein had a different pattern with the absence or a decrease of larger forms and the presence of a fast-moving **precipitating** peak, suggesting degradation of the vWF:Ag in FVIII concentrates. The electrophoretic mobility of **fibronectin**, .alpha.2-AP and AT-III was normal. AII PCC showed a more anodic mobility of **factor** IX. .alpha.2-AP also exhibited a different electrophoretic pattern to that of normal plasma...  
...of AT-III was also found in heparin-binding studies. The techniques used in the **purification** procedures are probably the mechanism responsible for the partial denaturing of these proteins.

...REGISTRY NUMBERS: **FACTOR** -VIII...

... **FACTOR** -VIII...

... **FACTOR** -VIII...

... **FACTOR** -IX...

... **FACTOR** -XIII...

... **FACTOR** -II...

... **FACTOR** -II

DESCRIPTORS: HUMAN HEMATOLOGIC-DRUG **FACTOR** -IX ALPHA-2 ANTIPLASMIN **FACTOR** -XIII **FACTOR** -II ANTITHROMBIN III **FIBRONECTIN**

DESCRIPTORS:

CHEMICALS & BIOCHEMICALS: **FACTOR** -VIII...

... **FACTOR** -VIII...

... **FACTOR** -VIII...

... **FACTOR** -IX...

... **FACTOR** -XIII...

... **FACTOR** -II...

... **FACTOR** -II

7/6,K/4 (Item 1 from file: 34)  
DIALOG(R)File 34:(c) 2008 The Thomson Corp. All rts. reserv.

06697763 Genuine Article#: ZL472 Number of References: 23  
Title: Enzymatic and kinetic properties of blood coagulation factor  
XIIIa and guinea pig liver transglutaminase utilizing

(6-[N-(4-aminobutyl)-N-ethylamino]-2,3-dihydrophthalazine-1,4-dione, as a novel, specific and sensitive chemiluminescent substrate (ABSTRACT AVAILABLE)

Publication date: 19980100

**Title:** Enzymatic and kinetic properties of blood coagulation factor XIIIa and guinea pig liver transglutaminase utilizing (6-[N-(4-aminobutyl)-N-ethylamino]-2,3...

...Abstract: novel and sensitive chemiluminescent assay is described to quantitate the acyl transfer activities of blood coagulation factor XIIIa or liver transglutaminase using aminobutyl-N-ethyl-isoluminol as acyl acceptor and N,N-dimethylcasein, human plasma fibrinogen or **fibronectin** as acyl donors. The method involved covalently linking aminobutyl-N-ethyl-isoluminol through its...

...protein-bound glutamine resulting in an isopeptide bond; a reaction catalysed by both transglutaminase and **factor XIIIa**. The protein-bound aminobutyl-N-ethyl-isoluminol was separated from non-conjugated amine by **precipitation** with trichloroacetic acid. The protein-amine conjugate was dissolved in 500 mmol/L NaOH, oxidized...

...ammonium persulphate and light emission quantitated using a luminometer. Optimal conditions were established to detect **factor XIIIa** and transglutaminase activities with the chemiluminescent assay. Specificity was demonstrated by lack of activity in the presence of ethylenediamine tetra-acetic acid or unactivated **factor XIII**, or boiled enzymes, and by competitive inhibition with putrescine and 5'-(biotinamido) pentylamine. The enzymatic and kinetic properties of **factor XIIIa** and transglutaminase in utilizing aminobutyl-N-ethyl-isoluminol as an acyl acceptor substrate were comprehensively documented. The reaction could be carried out in either a **purified** system or a complex plasma or cell lysates milieu. The assay is sensitive, specific, and...

...Identifiers--TRANSAMIDATING ENZYMES; CHEMI-LUMINESCENT; ASSAY; PURIFICATION; PROTEIN; TISSUES; LUMINOL; SITE

7/6,K/5 (Item 1 from file: 73)  
DIALOG(R)File 73:(c) 2008 Elsevier B.V. All rts. reserv.

0072901687 EMBASE No: 1985107103  
Coagulation proteins showing abnormal electrophoretic mobility in commercial concentrates of factor VIII and prothrombin complex  
December 1, 1984

Coagulation proteins showing abnormal electrophoretic mobility in commercial concentrates of factor VIII and prothrombin complex

Five commercial **factor VIII** (FVIII) concentrates and three prothrombin complex concentrates (PCC) were studied with reference to the qualitative evaluation of factors II, IX, **fibronectin**, alpha SUB 2-antiplasmin (alpha SUB 2-AP), antithrombin III (AT-III) and subunits A and S of FXIII by crossed-immunolectrophoresis (CIE) and von Willebrand **factor** antigen (vWF:Ag) by radio-CIE. This latter protein had a different pattern in the absence or a decrease of larger forms and the presence of a fast-moving **precipitating** peak, suggesting degradation of the vWF:Ag in FVIII concentrates. In contrast, the electrophoretic mobility of **fibronectin**,

alpha SUB 2-AP and AT-III was normal. All PCC showed a more anodic mobility of **factor IX**. alpha SUB 2-AP also exhibited a different electrophoretic pattern to that of normal...

...of AT-III was also found in heparin-binding studies. The techniques used in the **purification** procedures are probably the mechanism responsible for the partial denaturing of these proteins.

DRUG DESCRIPTORS:

\*blood clotting **factor 8**; \*blood clotting **factor 8** concentrate; \*

prothrombin; \*prothrombin complex

CAS REGISTRY NO.: 9001-27-8 (blood clotting **factor 8**); 37224-63-8 (prothrombin complex); 9001-26-7 (prothrombin)

7/6,K/6 (Item 1 from file: 155)

DIALOG(R)File 155:(c) format only 2008 Dialog. All rts. reserv.

11789238 PMID: 9608360

**Enzymatic and kinetic properties of blood coagulation factor XIIIa and guinea pig liver transglutaminase utilizing (6-[N-(4-aminobutyl)-N-ethylamino]-2,3-dihydropthalazine-1,4-dione, as a novel, specific and sensitive chemiluminescent substrate.**

Jan-Feb 1998

**Enzymatic and kinetic properties of blood coagulation factor XIIIa and guinea pig liver transglutaminase utilizing (6-[N-(4-aminobutyl)-N-ethylamino]-2,3...**

... novel and sensitive chemiluminescent assay is described to quantitate the acyl transfer activities of blood **coagulation factor XIIIa** or liver transglutaminase using aminobutyl-N-ethylisoluminol as acyl acceptor and N,N-dimethylcasein, human plasma fibrinogen or **fibronectin** as acyl donors. The method involved covalently linking aminobutyl-N-ethyl-isoluminol through its free...

... protein-bound glutamine resulting in an isopeptide bond; a reaction catalysed by both transglutaminase and **factor XIIIa**. The protein-bound aminobutyl-N-ethyl-isoluminol was separated from non-conjugated amine by **precipitation** with trichloroacetic acid. The protein-amine conjugate was dissolved in 500 mmol/L NaOH, oxidized...

...ammonium persulphate and light emission quantitated using a luminometer. Optimal conditions were established to detect **factor XIIIa** and transglutaminase activities with the chemiluminescent assay. Specificity was demonstrated by lack of activity in the presence of ethylenediamine tetra-acetic acid or unactivated **factor XIII**, or boiled enzymes, and by competitive inhibition with putrescine and 5'-biotinamido pentylamine. The enzymatic and kinetic properties of **factor XIIIa** and transglutaminase in utilizing aminobutyl-N-ethyl-isoluminol as an acyl acceptor substrate were comprehensively documented. The reaction could be carried out in either a **purified** system or a complex plasma or cell lysates milieu. The assay is sensitive, specific, and...

7/6,K/7 (Item 2 from file: 155)

DIALOG(R)File 155:(c) format only 2008 Dialog. All rts. reserv.

08924152 PMID: 1858340

[Production of a fibrinogen concentrate from small amounts of human

**autologous blood plasma and its short-term characteristics]**

Poluchenie kontsentrata fibrinogena iz nebol'shikh kolichestv plazmy autogennoi krovi cheloveka i ego kratkaih kharakteristik.  
Jan-Feb 1991

... was developed for production of fibrinogen concentrate from small amounts of human autogenous blood using **precipitation** with polyethylene glycol and ammonium sulfate. Maximal yield of fibrinogen was obtained using polyethylene glycol...

... and 6,000 daltons at concentrations 7% and 4.5%, respectively. The fibrinogen preparations included **fibronectin**, inhibitors of proteinases, **factor XIII** of blood **coagulation**, plasminogen. Sigma-Aminocapronic acid and contrical should be added during bloodletting as well as into...

Descriptors: \*Blood; \*Fibrinogen--isolation and **purification**--IP; Electrophoresis, Polyacrylamide Gel; **Factor XIII**--chemistry--CH; Fibrinogen--analysis--AN; Fibronectins--analysis--AN; Humans; Plasminogen--analysis--AN; Polyethylene Glycols...

Chemical Name: Fibronectins; Polyethylene Glycols; Protease Inhibitors; Fibrinogen; Plasminogen; **Factor XIII**

**7/6,K/8 (Item 3 from file: 155)**

DIALOG(R)File 155:(c) format only 2008 Dialog. All rts. reserv.

06712389 PMID: 3922084

The role of fibronectin in factor VIII/von Willebrand factor cryoprecipitation.

Mar 15 1985

The role of fibronectin in factor VIII/von Willebrand factor cryoprecipitation.

To evaluate the role of **fibronectin** (Fn) in **factor VIII** (FVIII) and von Willebrand **factor** (vWF) cryoprecipitation, **factor VIII** procoagulant activity, **factor VIII** coagulant antigen, **factor VIII**-related antigen and von Willebrand ristocetin cofactor activity were measured in cryoprecipitate and cryosupernatant...

...antibodies behaved differently: although their cryoprecipitate contained normal fibrinogen levels, neither FVIII nor FvWF was **precipitated**. Experiments performed with Fn-depleted plasma to which **purified fibronectin** had been added, and samples of plasma with decreased Fn levels (0.01 to 0...

Descriptors: \*Blood **Coagulation Factors**--isolation and **purification**--IP; \* **Factor VIII**--isolation and **purification**--IP; \*Fibronectins--blood--BL; \*von Willebrand **Factor**--isolation and **purification**--IP; Freezing; Humans; **Precipitation**

Chemical Name: Blood **Coagulation Factors**; Fibronectins; von Willebrand **Factor**; **Factor VIII**

**7/6,K/9 (Item 4 from file: 155)**

DIALOG(R)File 155:(c) format only 2008 Dialog. All rts. reserv.

06630779 PMID: 6442908

Coagulation proteins showing abnormal electrophoretic mobility in commercial concentrates of **factor VIII** and prothrombin complex.

1984

Coagulation proteins showing abnormal electrophoretic mobility in commercial concentrates of factor VIII and prothrombin complex.

Five commercial factor VIII (FVIII) concentrates and three prothrombin complex concentrates (PCC) were studied with reference to the qualitative evaluation of factors II, IX, fibronectin, alpha 2-antiplasmin (alpha 2-AP), antithrombin III (AT-III) and subunits A and S of FXIII by crossed-immunolectrophoresis (CIE) and von Willebrand factor antigen (vWF:Ag) by radio-CIE. This latter protein had a different pattern with the absence or a decrease of larger forms and the presence of a fast-moving precipitating peak, suggesting degradation of the vWF:Ag in FVIII concentrates. In contrast, the electrophoretic mobility of fibronectin, alpha 2-AP and AT-III was normal. All PCC showed a more anodic mobility of factor IX. alpha 2-AP also exhibited a different electrophoretic pattern to that of normal plasma...

...of AT-III was also found in heparin-binding studies. The techniques used in the purification procedures are probably the mechanism responsible for the partial denaturing of these proteins.

Descriptors: \*Blood Coagulation Factors--analysis--AN; \* Factor VIII --analysis--AN; Antithrombin III--analysis--AN; Blood Coagulation Factors --isolation and purification --IP; Blood Coagulation Factors--standards --ST; Blood Protein Electrophoresis; Counterimmunolectrophoresis; Drug Contamination; Factor VIII--isolation and purification --IP; Factor VIII--standards--ST; Fibronectins--analysis--AN; Humans; Protein Denaturation

Chemical Name: Blood Coagulation Factors; Fibronectins; prothrombin complex concentrates; Antithrombin III; Factor VIII

7/6,K/10 (Item 5 from file: 155)

DIALOG(R)File 155:(c) format only 2008 Dialog. All rts. reserv.

06555871 PMID: 6437941

Isolation of small molecular forms of Factor VIII/von Willebrand factor from plasma.

1984

Isolation of small molecular forms of Factor VIII/von Willebrand factor from plasma.

Cryoprecipitated factor VIII/von Willebrand factor (FVIII/vWF), freed of fibrinogen by clotting with calcium and Defibrase, was chromatographed on Sepharose...

... forms of FVIII/vWF comprised coprecipitated plasma proteins of similar molecular weights. The major contaminants, fibronectin and IgM, were removed by affinity chromatography on gelatin- and anti-IgM-agarose, respectively. Finally...

Descriptors: \*Blood Coagulation Factors--isolation and purification --IP; \* Factor VIII--isolation and purification --IP; \*von Willebrand Factor --isolation and purification --IP; Chromatography--methods--MT; Cold; Humans; Molecular Weight; Precipitation

Chemical Name: Blood Coagulation Factors; von Willebrand Factor ; Factor VIII

7/6,K/11 (Item 6 from file: 155)

DIALOG(R)File 155:(c) format only 2008 Dialog. All rts. reserv.

06237133 PMID: 6415800

[**Plasma fibronectin**]

La fibronectine plasmatische.

Jun 1983

[**Plasma fibronectin**]

**Fibronectin** (FN) is a glycoprotein (disulfite-bonded dimer of 200 to 220 Kd subunits) found in...

... like collagen, proteoglycans... FN fundamentally forms molecular complexes with collagen, fibrinogen or fibrin, heparin, activated **factor XIII**, bacteria, cellular membranes..., these various proteins binding with now well known functional "domains" on...

...also interacts with hemostatic and fibrinolytic systems, as component of the subendothelium (secreted, like Willebrand **factor**, by endothelial cells) and of platelet alpha-granules released by stimulated platelets. FN could then provoke platelet spreading on the subendothelium surface after collagen-platelet adhesion, triggered by Willebrand **factor**, has happened. FN is a part of the fibrinous clot. It participates in anchorage of...

; Animals; Blood **Coagulation**; Cell Adhesion; Cell Movement; Cell Transformation, Viral; Chemistry; Chromatography, Affinity; Collagen--metabolism--ME; **Factor VIII**--metabolism--ME; Fibrin--metabolism--ME; Fibronectin--metabolism--ME; Fibroblasts--metabolism--ME; Fibronectins--analysis--AN; Fibronectins--isolation and **purification**--IP; Heparin--blood--BL; Humans; Molecular Weight; Opsonin Proteins; Peptide Hydrolases--pharmacology--PD; **Precipitation**; Rats; Wound Healing

Chemical Name: Fibronectins; Opsonin Proteins; cryoprecipitate coagulum; **Factor VIII**; Fibrin; Fibronectin; Heparin; Collagen; Peptide Hydrolases

7/6,K/12 (Item 1 from file: 357)

DIALOG(R)File 357:(c) 2008 The Thomson Corp. All rts. reserv.

0411605 DBR Accession No.: 2006-25101

Recombinant production of proteins comprises subjecting a suspension of the cells to a non-physiologically increased concentration of at least one ionic substance, e.g. amino acid, prior to harvest of protein - recombinant protein production via plasmid expression in cell culture for disease therapy 2006

...ABSTRACT: FIX, FIXa, FVII, FVIII, FVIIIa, FXI, FXIa, FXII, FXIIa, FXIII and FXIIIa, von Willebrand **factor**, transport proteins including albumin, transferrin, ceruloplasmin, haptoglobin, hemoglobin and hemopexin, protease inhibitors including beta-antithrombin, alpha-antithrombin, alpha2-macroglobulin, C1-inhibitor, tissue **factor** pathway inhibitor (TFPI), heparin cofactor II, protein C inhibitor (PAI-3), Protein C and Protein...

... reactive protein and other proteins including histidine-rich glycoprotein, mannan binding lectin, C4-binding protein, **fibronectin**, GC-globulin, plasminogen, blood factors such as erythropoietin, Interferon, tumor factors, tPA, gCSF, or their derivatives and muteins, more preferably the plasma protein is a human **factor VIII** or a human

FIX protein or its mutein, even more preferably is a B-domain deleted factor VIII protein, most preferably is the factor VIII mutein having a sequence comprising 1459 amino acids (SEQ ID NOS: 4 or 6...

... magnetic fields and ultra filtration. The isolation of the protein from the medium and its **purification** is effected by using at least one technique selected from immuno-affinity chromatography, affinity chromatography, protein **precipitation**, buffer exchanges, ionic exchange chromatography, hydrophobic interaction chromatography, mixed mode hydrophobic/ion exchange chromatography media...

... chromatography, carbohydrate affinity like lectin or heparin affinity chromatography, size-exclusion chromatography, electrophoresis, dialysis, different **precipitation** agents such as polyethylene glycol, ammonium sulphate, ethanol, hydroxy apatite adsorption, filter membrane adsorption, ligands coupled to magnetic particles etc. The carrier used for the chromatography **purification**, is selected from resins, particles, beads, membranes, hollow fiber or similar. The isolation of the...

... ultra filtration. The method is performed under sterile conditions, where the medium and/or the **purified** protein is subjected to a virus inactivation and/or removal step, and/or where the...

... filtrate of the micro filtration system. Preferred Pharmaceutical Composition: The pharmaceutical composition comprises a blood **coagulation factor**, preferably a FVIII or FIX protein and is for treatment of hemophiliacs. ACTIVITY - Hemostatic. No...

DESCRIPTORS: recombinant fibrinogen protein, prothrombin, **Factor -X**, **Factor -IX**, **Factor -VII**, **Factor -VIII**, **Factor -XI**, **Factor -XII**, **Factor -XIII**, von Willebrand **factor**, transport protein prep., vector-mediated gene transfer expression in host cell, immortalized mammal cell continuous...

? s s6 and pH  
22 S6  
4138455 PH  
S8 4 S6 AND PH  
? t s8/6,k/1-4

8/6,K/1 (Item 1 from file: 155)  
DIALOG(R)File 155:(c) format only 2008 Dialog. All rts. reserv.

13892079 PMID: 12186399

Comparative studies of a humanized anti-glycoprotein IIb/IIIa monoclonal antibody, YM337, and abciximab on in vitro antiplatelet effect and binding properties.

Aug 2002

... aggregation caused by all agonists tested except ristocetin. Further, both inhibited human platelet adhesion to **von Willebrand factor**, fibrinogen, **fibronectin** and subendothelial matrix with similar potency. Fibrinogen binding to washed platelets was dose-dependently inhibited...

... 700 +/- 3,000 for YM337 and 76,000 +/- 5,400 for abciximab. GPIIb/IIIa was **precipitated** from the solubilized fraction of platelets by both agents. In contrast, integrin alphavbeta3 was **precipitated** from the solubilized fraction of human umbilical vein endothelial cells by abciximab but not by YM337. Fibrinogen binding to **purified** GPIIb/IIIa was

dose-dependently inhibited by both agents. In contrast, vitronectin binding to **purified** integrin alphavbeta3 was dose-dependently inhibited by abciximab but not by YM337, supporting the idea...

...; Immunoglobulin Fab Fragments--metabolism--ME; Platelet Adhesiveness; Platelet Aggregation--drug effects--DE; Platelet Aggregation--physiology--PH ; Platelet Aggregation Inhibitors--metabolism--ME; Platelet Glycoprotein GPIb-IIIa Complex--antagonists and inhibitors--AI; Protein Binding--drug effects--DE; Protein Binding--physiology--PH

**8/6,K/2 (Item 2 from file: 155)**  
DIALOG(R)File 155:(c) format only 2008 Dialog. All rts. reserv.

08600770 PMID: 2119525

**Development of a heat-treated factor VIII/ von Willebrand factor concentrate prepared from heparinized plasma.**  
Jun 28 1990

**Development of a heat-treated factor VIII/ von Willebrand factor concentrate prepared from heparinized plasma.**

A high yield, intermediate purity **factor VIII** concentrate derived from heparinized plasma has been developed which can be heat-treated at...

... which may be present. After cold reprecipitation of the heparinized cryoprecipitate (CRC), the resolubilized CRC **precipitate** was adjusted to 25-30 mg/ml protein and **pH** 6.35 +/- 0.1 and incubated for 1 h at 8 degrees C. After centrifugation to remove the **precipitated** fibrinogen and **fibronectin** , a **factor VIII**-rich supernatant can be recovered which contains greater than 500 units of **VIII:C**...

...at a purity of 1.5 U/mg protein. Adjusted to 50 mM glycine and **pH** 6.8, the product can be lyophilized and heat-treated at 60 degrees C/72...

...9 U/mg. When adjusted to 50 mM glycine and 1-2% (w/v) sucrose ( **pH** 6.8), lyophilized and heat treated at 60 degrees C, 68 degrees C or 80...

... v) sucrose even after the severe heat-treatment at 80 degrees C. In addition, the **von Willebrand factor** multimers are similar in size and triplet pattern to those observed in routine cryoprecipitate preparations.

Descriptors: \*Factor VIII--isolation and **purification**--IP; \* **von Willebrand Factor** --isolation and **purification**--IP; Cold; Freeze Drying; Heat; Heparin; Humans; Macromolecular Substances; Plasma--analysis--AN; Plasma--drug effects--DE; **Precipitation** ; Solubility; Water--analysis--AN

Chemical Name: Macromolecular Substances; **von Willebrand Factor** ; Water; **Factor VIII**; Heparin

**8/6,K/3 (Item 3 from file: 155)**  
DIALOG(R)File 155:(c) format only 2008 Dialog. All rts. reserv.

08057133 PMID: 2495039

**Some characteristics of aggregates of IgG and plasma proteins in heat-treated factor VIII concentrates.**  
Mar 1989

Some characteristics of aggregates of IgG and plasma proteins in

**heat-treated factor VIII concentrates.**

Eight batches of commercial heat-treated and one untreated **factor VIII** concentrate from 6 producers were analyzed for their content of IgG, IgG subclasses, IgG...

... for anticomplement activity. Methods used were thin-layer gel filtration, immuno-gel filtration, spot immuno- **precipitate** assay in a double antibody version and an agarose plate haemolysis inhibition assay of complement...

... compared to normal serum and intravenous immunoglobulin, one to four of the following plasma proteins; **fibronectin**, fibrinogen, **von Willebrand factor** antigen, Clq, albumin and IgA. Three batches from two producers had high anticomplementary activity, presumably...

Descriptors: \*Blood Proteins--isolation and **purification**--IP; \* Factor VIII--analysis--AN; \*Heat; \*Immunoglobulin G--isolation and **purification**--IP...; Thin Layer; Complement System Proteins--immunology--IM; Humans; Immunoglobulin G--classification--CL; Immunoglobulin G--physiology-- PH; Macromolecular Substances; Precipitin Tests

Chemical Name: Blood Proteins; Immunoglobulin G; Macromolecular Substances; **Factor VIII**; Complement System Proteins

8/6,K/4 (Item 1 from file: 357)

DIALOG(R) File 357:(c) 2008 The Thomson Corp. All rts. reserv.

0411605 DBR Accession No.: 2006-25101

Recombinant production of proteins comprises subjecting a suspension of the cells to a non-physiologically increased concentration of at least one ionic substance, e.g. amino acid, prior to harvest of protein - recombinant protein production via plasmid expression in cell culture for disease therapy 2006

...ABSTRACT: FX, Fa, FIX, FIXa, FVII, FVIIa, FVIII, FVIIIa, FXI, FXIa, FXII, FXIIa, FXIII and FXIIIa, **von Willebrand factor**, transport proteins including albumin, transferin, ceruloplasmin, haptoglobin, hemoglobin and hemopexin, protease inhibitors including beta-antithrombin, alpha-antithrombin, alpha2-macroglobulin, C1-inhibitor, tissue **factor** pathway inhibitor (TFPI), heparin cofactor II, protein C inhibitor (PAI-3), Protein C and Protein...

... reactive protein and other proteins including histidine-rich glycoprotein, mannan binding lectin, C4-binding protein, **fibronectin**, GC-globulin, plasminogen, blood factors such as erythropoietin, Interferon, tumor factors, TPA, gCSF, or their derivatives and muteins, more preferably the plasma protein is a human **factor VIII** or a human FIX protein or its mutein, even more preferably is a B-domain deleted **factor VIII** protein, most preferably is the **factor VIII** mutein having a sequence comprising 1459 amino acids (SEQ ID NOS: 4 or 6...

... of non-ionic detergents. The release composition further comprises a buffering substance to stabilize the **pH**, preferably the buffering substance is selected from Goods buffer substances, including HEPES, MES, TRIS, etc. The **pH** of the cell suspension when subjected to the increased concentration of the at least one...

... magnetic fields and ultra filtration. The isolation of the protein from

the medium and its **purification** is effected by using at least one technique selected from immuno-affinity chromatography, affinity chromatography, protein **precipitation**, buffer exchanges, ionic exchange chromatography, hydrophobic interaction chromatography, mixed mode hydrophobic/ion exchange chromatography media...

... chromatography, carbohydrate affinity like lectin or heparin affinity chromatography, size-exclusion chromatography, electrophoresis, dialysis, different **precipitation** agents such as polyethylene glycol, ammonium sulphate, ethanol, hydroxy apatite adsorption, filter membrane adsorption, ligands coupled to magnetic particles etc. The carrier used for the chromatography **purification**, is selected from resins, particles, beads, membranes, hollow fiber or similar. The isolation of the...

... ultra filtration. The method is performed under sterile conditions, where the medium and/or the **purified** protein is subjected to a virus inactivation and/or removal step, and/or where the...

... of the micro filtration system. Preferred Pharmaceutical Composition: The pharmaceutical composition comprises a blood coagulation **factor**, preferably a FVIII or FIX protein and is for treatment of hemophiliacs. ACTIVITY - Hemostatic. No...

DESCRIPTORS: recombinant fibrinogen protein, prothrombin, **Factor -X**, **Factor -IX**, **Factor -VII**, **Factor -VIII**, **Factor -XI**, **Factor -XII**, **Factor -XIII**, **von Willebrand factor**, transport protein prep., vector-mediated gene transfer expression in host cell, immortalized mammal cell continuous...

? t s8/9,k/2

8/9,K/2 (Item 2 from file: 155)

DIALOG(R)File 155: MEDLINE(R)

(c) format only 2008 Dialog. All rts. reserv.

08600770 PMID: 2119525

Development of a heat-treated factor VIII/ von Willebrand factor concentrate prepared from heparinized plasma.

Palmer D S; Ganz P R; Perkins H; Rosborough D; Rock G  
Ottawa Centre, Canadian Red Cross, Blood Transfusion Service, Ontario.  
Thrombosis and haemostasis (GERMANY, WEST) Jun 28 1990, 63 (3)  
p392-402, ISSN 0340-6245--Print Journal Code: 7608063

Publishing Model Print

Document type: Journal Article; Research Support, Non-U.S. Gov't

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

Subfile: INDEX MEDICUS

A high yield, intermediate purity **factor** VIII concentrate derived from heparinized plasma has been developed which can be heat-treated at 60 degrees C, 68 degrees C or 80 degrees C/72 h to permit inactivation of viral contaminants which may be present. After cold reprecipitation of the heparinized cryoprecipitate (CRC), the resolubilized CRC **precipitate** was adjusted to 25-30 mg/ml protein and **pH** 6.35 +/- 0.1 and incubated for 1 h at 8 degrees C. After centrifugation to remove the **precipitated** fibrinogen and **fibrinectin**, a **factor** VIII-rich supernatant can be recovered which contains greater than 500 units of VIII:C per liter of starting plasma (Method I product) at a purity of 1.5 U/mg protein.

Adjusted to 50 mM glycine and **pH** 6.8, the product can be lyophilized and heat-treated at 60 degrees C/72 h without a significant loss of VIII:C activity. However, at 68 degrees C or 80 degrees C/72 h, temperatures now reported to be more effective in viral inactivation, the recoveries were reduced to 68 and 33% respectively. Significantly improved recoveries after heat-treatment (HT) at 68 degrees C or 80 degrees C/72 h were achieved if the 8 degrees C supernatant product was prepared by a modified procedure (Method II). This further reduces the fibrinogen content of the product while maintaining VIII:C yields greater than 500 U/l at a purity of 1.9 U/mg. When adjusted to 50 mM glycine and 1-2% (w/v) sucrose (**pH** 6.8), lyophilized and heat treated at 60 degrees C, 68 degrees C or 80 degrees C/72 h, the VIII:C recoveries of Method II product were 88-100%, 79-84% and 80-83% of pre-HT levels respectively. The yield of VIII:C was greater than 400 U/l at a purity of 1.6-1.4 U/mg at 1-2% (w/v) sucrose even after the severe heat-treatment at 80 degrees C. In addition, the **von Willebrand factor** multimers are similar in size and triplet pattern to those observed in routine cryoprecipitate preparations.

Descriptors: \*Factor VIII-isolation and purification --IP; \* **von Willebrand Factor** --isolation and purification --IP; Cold; Freeze Drying; Heat; Heparin; Humans; Macromolecular Substances; Plasma--analysis --AN; Plasma--drug effects--DE; Precipitation ; Solubility; Water --analysis--AN

CAS Registry No.: 0 (Macromolecular Substances); 0 (von Willebrand Factor); 7732-18-5 (Water); 9001-27-8 (Factor VIII); 9005-49-6 (Heparin)

Record Date Created: 19901019

Record Date Completed: 19901019

**Development of a heat-treated factor VIII/ von Willebrand factor concentrate prepared from heparinized plasma.**

A high yield, intermediate purity **factor VIII** concentrate derived from heparinized plasma has been developed which can be heat-treated at...

... which may be present. After cold reprecipitation of the heparinized cryoprecipitate (CRC), the resolubilized CRC **precipitate** was adjusted to 25-30 mg/ml protein and **pH** 6.35 +/- 0.1 and incubated for 1 h at 8 degrees C. After centrifugation to remove the **precipitated** fibrinogen and **fibronectin** , a **factor VIII**-rich supernatant can be recovered which contains greater than 500 units of VIII:C...

...at a purity of 1.5 U/mg protein. Adjusted to 50 mM glycine and **pH** 6.8, the product can be lyophilized and heat-treated at 60 degrees C/72... . . . 9 U/mg. When adjusted to 50 mM glycine and 1-2% (w/v) sucrose (**pH** 6.8), lyophilized and heat treated at 60 degrees C, 68 degrees C or 80...

... v) sucrose even after the severe heat-treatment at 80 degrees C. In addition, the **von Willebrand factor** multimers are similar in size and triplet pattern to those observed in routine cryoprecipitate preparations.

Descriptors: \*Factor VIII-isolation and purification --IP; \* **von Willebrand Factor** --isolation and purification --IP; Cold; Freeze Drying; Heat; Heparin; Humans; Macromolecular Substances; Plasma--analysis --AN; Plasma--drug effects--DE; Precipitation ; Solubility; Water --analysis--AN

Chemical Name: Macromolecular Substances; **von Willebrand Factor** ; Water; **Factor VIII**; Heparin

? logoff y

23jan08 11:05:20 User276653 Session D136.2

	\$7.84	1.306	DialUnits	File5
	\$2.30	1	Type(s)	in Format 9
	\$0.54	3	Type(s)	in Format 95 (KWIC)
	\$2.84	4	Types	
\$10.68	Estimated cost	File5		
	\$0.80	0.130	DialUnits	File24
\$0.80	Estimated cost	File24		
	\$0.24	0.039	DialUnits	File28
\$0.24	Estimated cost	File28		
	\$17.94	0.674	DialUnits	File34
	\$0.46	1	Type(s)	in Format 95 (KWIC)
	\$0.46	1	Types	
\$18.40	Estimated cost	File34		
	\$0.29	0.071	DialUnits	File35
\$0.29	Estimated cost	File35		
	\$0.26	0.037	DialUnits	File40
\$0.26	Estimated cost	File40		
	\$0.37	0.059	DialUnits	File41
\$0.37	Estimated cost	File41		
	\$0.68	0.135	DialUnits	File45
\$0.68	Estimated cost	File45		
	\$0.73	0.158	DialUnits	File50
\$0.73	Estimated cost	File50		
	\$0.19	0.045	DialUnits	File65
\$0.19	Estimated cost	File65		
	\$1.90	0.189	DialUnits	File71
\$1.90	Estimated cost	File71		
	\$11.34	0.883	DialUnits	File73
	\$0.42	1	Type(s)	in Format 95 (KWIC)
	\$0.42	1	Types	
\$11.76	Estimated cost	File73		
	\$0.18	0.042	DialUnits	File91
\$0.18	Estimated cost	File91		
	\$0.19	0.045	DialUnits	File98
\$0.19	Estimated cost	File98		
	\$0.13	0.023	DialUnits	File110
\$0.13	Estimated cost	File110		
	\$0.59	0.104	DialUnits	File135
\$0.59	Estimated cost	File135		
	\$0.35	0.056	DialUnits	File136
\$0.35	Estimated cost	File136		
	\$0.11	0.037	DialUnits	File143
\$0.11	Estimated cost	File143		
	\$2.54	0.513	DialUnits	File144
\$2.54	Estimated cost	File144		
	\$3.28	0.965	DialUnits	File155
	\$0.44	2	Type(s)	in Format 9
	\$0.45	9	Type(s)	in Format 95 (KWIC)
	\$0.89	11	Types	
\$4.17	Estimated cost	File155		
	\$0.15	0.042	DialUnits	File164
\$0.15	Estimated cost	File164		
	\$0.58	0.045	DialUnits	File172
\$0.58	Estimated cost	File172		
	\$0.38	0.062	DialUnits	File185
\$0.38	Estimated cost	File185		
	\$3.14	0.124	DialUnits	File357

\$0.64 2 Type(s) in Format 95 (KWIC)  
      \$0.64 2 Types  
\$3.78 Estimated cost File357  
\$0.12    0.034 DialUnits File369  
\$0.12 Estimated cost File369  
\$0.14    0.039 DialUnits File370  
\$0.14 Estimated cost File370  
\$0.00    0.054 DialUnits File391  
\$0.00 Estimated cost File391  
\$2.93    0.110 DialUnits File434  
\$2.93 Estimated cost File434  
\$0.23    0.037 DialUnits File467  
\$0.23 Estimated cost File467  
\$2.40    OneSearch, 29 files, 6.058 DialUnits FileOS  
\$2.40    TELNET  
\$65.27 Estimated cost this search  
\$65.30 Estimated total session cost 6.325 DialUnits

Logoff: level 05.20.01 D 11:05:20

You are now logged off